Getein Biotech, Inc (SHA:603387)
China · Delayed Price · Currency is CNY 8.24
-0.31 (-3.63%)
Nov 13, 2026, 3:00 PM CST
Getein Biotech Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 351.34 | 313.88 | 351.6 | 484.33 | 646.25 | 968.9 |
Trading Asset Securities | 1,313 | 912.63 | 648.88 | 451.91 | 511.14 | 612.68 |
Cash & Short-Term Investments | 1,664 | 1,227 | 1,000 | 936.24 | 1,157 | 1,582 |
Cash Growth | 45.99% | 22.59% | 6.86% | -19.11% | -26.82% | 13.26% |
Accounts Receivable | 311.2 | 362.09 | 359.65 | 453.18 | 502.1 | 445.96 |
Other Receivables | 17.4 | 71.53 | 50.29 | 133.31 | 37.36 | 37.45 |
Receivables | 328.6 | 433.62 | 409.94 | 586.49 | 539.45 | 483.41 |
Inventory | 192.63 | 183.83 | 194.46 | 229.71 | 269.39 | 252.3 |
Other Current Assets | 281.21 | 458.73 | 252.18 | 398.75 | 433.12 | 48.13 |
Total Current Assets | 2,467 | 2,303 | 1,857 | 2,151 | 2,399 | 2,365 |
Property, Plant & Equipment | 730.26 | 724.05 | 707.48 | 703.86 | 556.49 | 452.2 |
Long-Term Investments | 158.36 | 449.42 | 889.75 | 641.21 | 223.6 | 142.86 |
Goodwill | 12.02 | 12.02 | 0.31 | 26.14 | 26.14 | 26.14 |
Other Intangible Assets | 162.79 | 172.94 | 141.55 | 113.79 | 103.91 | 77.21 |
Long-Term Accounts Receivable | 0.7 | 1.98 | 4.9 | 8.23 | 9.25 | 10.93 |
Long-Term Deferred Tax Assets | 64.18 | 57.83 | 47.89 | 43.18 | 35.48 | 14.92 |
Long-Term Deferred Charges | 34.61 | 31.49 | 55.07 | 80.12 | 51.05 | 43.68 |
Other Long-Term Assets | 67.84 | 3.52 | 3.39 | 3.92 | 273.63 | 4.56 |
Total Assets | 3,698 | 3,756 | 3,707 | 3,772 | 3,679 | 3,138 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 184.91 | 126.65 | 77.4 | 73.73 | 102.95 | 110.97 |
Accrued Expenses | 55.54 | 98.95 | 98.39 | 103.03 | 120.22 | 85 |
Short-Term Debt | 275.83 | 479.89 | 575.57 | 641.29 | 551.94 | 464.37 |
Current Portion of Long-Term Debt | - | - | - | 12.89 | 25.8 | 0.2 |
Current Portion of Leases | 0.42 | 0.77 | 4.38 | 9.79 | 5.63 | 2.1 |
Current Income Taxes Payable | 24.4 | 10.55 | 12.2 | 9.58 | 9.04 | 10.48 |
Current Unearned Revenue | 46.49 | 39.35 | 34.87 | 38.17 | 75.37 | 94.29 |
Other Current Liabilities | 55.49 | 99.01 | 137.22 | 90.91 | 67.12 | 46.08 |
Total Current Liabilities | 643.08 | 855.17 | 940.01 | 979.38 | 958.06 | 813.48 |
Long-Term Debt | - | - | - | - | 3 | 27.78 |
Long-Term Leases | 1.03 | 1.3 | 1.62 | 2.71 | 4.65 | 2 |
Long-Term Unearned Revenue | 13.97 | 15.71 | 18.3 | 20.88 | 23.47 | 5.87 |
Long-Term Deferred Tax Liabilities | 28.71 | 24.37 | 26.48 | 27.41 | 24.2 | 13.96 |
Other Long-Term Liabilities | - | - | - | - | 0.91 | 0.8 |
Total Liabilities | 686.8 | 896.55 | 986.42 | 1,030 | 1,014 | 863.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 507.15 | 507.15 | 507.15 | 507.15 | 507.15 | 363.81 |
Additional Paid-In Capital | 314.73 | 236.9 | 236.18 | 314.01 | 318.24 | 511.58 |
Retained Earnings | 2,075 | 1,995 | 1,865 | 1,732 | 1,655 | 1,280 |
Treasury Stock | -5.76 | - | - | - | - | -50 |
Comprehensive Income & Other | 14.46 | 13.84 | 10.16 | 5.87 | 1.69 | 1.37 |
Total Common Equity | 2,906 | 2,753 | 2,619 | 2,559 | 2,482 | 2,106 |
Minority Interest | 105.04 | 106.65 | 101.99 | 181.92 | 182.13 | 167.63 |
Shareholders' Equity | 3,011 | 2,859 | 2,721 | 2,741 | 2,665 | 2,274 |
Total Liabilities & Equity | 3,698 | 3,756 | 3,707 | 3,772 | 3,679 | 3,138 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 277.28 | 481.96 | 581.57 | 666.68 | 591.02 | 496.44 |
Net Cash (Debt) | 1,387 | 744.54 | 418.9 | 269.56 | 566.37 | 1,085 |
Net Cash Growth | 172.51% | 77.74% | 55.40% | -52.41% | -47.81% | 7.27% |
Net Cash Per Share | 2.75 | 1.48 | 0.82 | 0.53 | 1.11 | 2.12 |
Filing Date Shares Outstanding | 491.85 | 507.15 | 507.15 | 507.15 | 507.15 | 507.15 |
Total Common Shares Outstanding | 491.85 | 507.15 | 507.15 | 507.15 | 507.15 | 507.15 |
Working Capital | 1,824 | 1,448 | 917.03 | 1,172 | 1,441 | 1,552 |
Book Value Per Share | 5.91 | 5.43 | 5.16 | 5.05 | 4.89 | 4.15 |
Tangible Book Value | 2,731 | 2,568 | 2,477 | 2,419 | 2,352 | 2,003 |
Tangible Book Value Per Share | 5.55 | 5.06 | 4.88 | 4.77 | 4.64 | 3.95 |
Buildings | - | 285.91 | 273.29 | 247.34 | 243.57 | 240.18 |
Machinery | - | 528.69 | 527.67 | 529.3 | 440.02 | 296.94 |
Construction In Progress | - | 272.63 | 225.08 | 205.76 | 86.37 | 80.86 |